Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib combinations in relapsed or refractory B-cell lymphoma
NCT03424122Phase 1Completed
- Sponsor
- Incyte
- Start
- Jul 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of parsaclisib in B cell lymphoma (3 arms), sponsored by Incyte. Primary endpoint: Treatment-Emergent Adverse Events at 12 months. Started Jul 2018; status: completed.
02
Drugs
parsaclisib
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03424122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03424122.